investors

Immuneel is championing a momentous change—one that is human, medical, technological and economic. Join us.

A bold initiative to disrupt the landscape of cancer treatment in India, Immuneel is a privately-owned Indian clinical stage startup company established in 2018, and seed-funded through angel investments and institutional capital.

A first mover in India, Immuneel is pioneering the business and care delivery models which will transform the way cell and gene therapies are developed and manufactured while alleviating the suffering of an under-served population.

With an inspired leadership team and a wide sweep of capabilities being built, Immuneel has garnered support from leading investors across hospitals, corporates and institutions on its journey towards scale, reliability and speed.

Please contact investors@immuneel.com for any queries related to investor relations.

press releases
Download our latest press release
13th December, 2022
Immuneel Therapeutics Presents Early data from India for Varnimcabtagene autoleucel (IMAGINE, Phase 2) at ASH Annual Meeting 2022, USA.
Read more
21st June, 2022
Biotech start-up Immuneel Therapeutics announces India’s first Phase II patient trials for CAR-T cancer therapies alongside a USD 15 million Series A financing
Read more
18th January, 2021
Immuneel Announces the Inauguration of India’s first Integrated Cell Therapy Development and Manufacturing Facility
Read more
13th October, 2020
Immuneel Therapeutics, Hospital Clínic de Barcelona & Institut d’Investigacions Biomèdiques August Pi i Sunyer Announce a Strategic collaboration & a License Agreement.
Read more
media

Immuneel story has the attention and interest of the business press and technology writers

Read or watch what the press says about us
Please contact business.communications@immuneel.com for any queries related to media.
Advancements in Cell and Gene Therapies: A Glimpse into the Future of Cancer Treatment with CAR-T cell immunotherapy
CAR-T cell therapy is evidence of the amazing advancements in medical research in the worldwide battle against cancer.
ET Health
Read full story
Reimagining pharma and healthcare for India@100. Industry Report featuring Immuneel.
With the evolving global innovation landscape and country’s ambition for 2047, the next frontier for India is to focus on transformative innovation.
EY
Read full story
Immuneel presents exciting primary endpoint data & results from the IMAGINE study with 9 scientific abstracts at the 65th American Society of Hematology, Annual Meeting, San Diego, USA.
American Society of Hematology 2023
Read full story
Dr. Arun Anand talks to Dr. Bruce Levine on future of cancer treatment and access in the cell therapy space globally.
Immuneel Podcast
See Video
Dr Arun Anand and Dr Bruce speak with Express Pharma on cutting edge cell & gene therapy
Express Pharma
See Video
Immuneel won the ‘Innovation in Cell and Gene Therapy’ award and Dr Arun Anand our Board Director & COO, was honoured with ‘BioPharma Leader of the Year’ award, at BioPharma Honours 2023
Biopharma Hounours award is aimed at honouring individuals/organizations for their innovation & excellence in Biopharma Industry
BioPharma Honours 2023
Read full story
Immuneel Therapeutics paediatric subset data from IMAGINE study in India presented at SIOP 2023, Ottawa, Canada & won best poster award
International Society of Paediatric Oncology 2023
Read full story
Dr Arun Anand & Prachi Dubey talk to India Today in Health Wealth podcast about fascinating world of immunotherapy
India Today
See Video
The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023.
Some of the most provocative cell therapy work is happening halfway around the globe from Kendall Square, on the eighth floor of a hospital in Bengaluru, India.
Endpoints 11
Read full story
Immuneel honoured with ‘The Most Promising Cell & Gene Therapy Startup in APAC’ at the Asia Pacific Cell & Gene Therapy Excellence Awards 2023
Asia Pacific CGT Excellence Awards 2023 seeks to give recognition to exceptional Cell & Gene Therapy Pioneers, Researchers, Innovators & Manufacturers that f…
IMAPAC
Read full story
Cancer and a bespoke therapy: Immuneel Therapeutics COO Dr Arun Anand weighs in
In terms of sheer wizardry, the T-cell therapy technically deserves the prize. The therapy technically is so efficient that the T cells remain constantly vig…
Money Control
Read full story
Dr. Arun Anand presents at the Plenary session on ‘Global Expansion of CAR T – Cell Therapy – India’
Cellicon Valley 2023
See Video
Immuneel Therapeutics presents updated & exciting results for Varnimcabtagene Autoleucel (IMN-003A) from the IMAGINE study at EHA Annual Meeting 2023, Frankfurt, Germany
European Haematology Association 2023
Read full story
Immuneel Therapeutics Presents early correlative science data from IMAGINE study in India at ISCT 2023, Paris, France
International Society for Cell & Gene Therapy 2023
Read full story
Dr. Arun Anand sharing insights with EY on the side-lines of BioAsia 2023 about developing a market for CAR-T therapy in India.
EY
See Video
Big data set to transform drug R&D to enable scalable, affordable therapies – Panel discussion at BioAsia 2023
To discuss the role of data and technology in the pharma industry, experts shared their insights during the panel ‘Data, analytics and technology to transfor…
ET Healthworld
Read full story
Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets
Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘jou…
Scrip
Read full story
Dr. Arun Anand sharing insights on The COO Collective by ServiceNow and Forbes India.
Forbes India
See Video
World Cancer Day 2023: A look at the top treatment breakthroughs in 2022
From new ways of conducting radiation therapies and vaccines to bone marrow transplants, this year shed a ray of hope in the oncology sphere.
CNBCTV18
Read full story
Providing affordable cancer treatment in India paramount: Physician
Renowned cancer physician and author Siddhartha Mukherjee on Tuesday said one of the very important goals for him and his team is to make Chimeric Antigen Re…
The Hindu
Read full story
Siddhartha Mukherjee’s start-up to file trial data for cancer therapy
The move aims to make the advanced CAR-T cell therapy for cancers commercially available in India.
Hindustan Times (East UP)
Read full story
This World: Could a new cell therapy method bring a cure for cancer?
WION TV
See Video
Global data on the efficacy of CAR T-cell therapy for cancer looks very good’: Dr Siddhartha Mukherjee
The Indian Express
See Video
Is an Indian cure for blood cancer in sight?
How interim results of CAR (Chimeric Antigen Receptor)-T therapy from Bengaluru start-up Immuneel lend hope for blood cancer patients in India.
India Today
Read full story
India’s first Phase 2 multi-centre CAR-T cell therapy study gives promising results
Immuneel Therapeutics presents early data from India for Varnimcabtagene autoleucel at ASH Annual Meeting 2022, New Orleans, USA
BioSpectrum
Read full story
Dr. Arun Anand speaking at the Summit, “Biotech Future: Cell & Gene Therapy” session.
Bengaluru Tech Summit 2022
See Video
Aiming for sustainable innovation with affordable CAR-T therapy in India: Arun Anand, COO, Immuneel Therapeutics
Aiming to revolutionise the cancer therapy treatment in India, Immuneel Therapeutics hopes to bring down the cost of CAR-T therapy for patients.
MoneyControl
Read full story
Startup backed by Kiran Mazumdar-Shaw to begin clinical trial for CAR-T cancer treatment
Immuneel Therapeutics has exclusive rights to CD19 CAR-T from Spain to develop and commercialize the therapy in India via tech transfer. CAR-T therapies have…
CNBC TV18
Read full story
Immuneel Therapeutics raises $15 million in funding
Immuneel Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular immunotherapies for …
The Economic Times
Read full story
Kiran Mazumdar-Shaw co-founded biotech startup raises $15 mn in Series A funding
Established in 2019, Immuneel has raised around $28 million till date from venture capital firms as well as individuals, Shaw told VCCircle in an interaction
Mint
Read full story
Talks by Dr. Bala S. Manian and Dr. Bruce Levine on Cell & Gene Therapy.
Celltalk 2021 Webinar
See Video
CAR T-cell therapy roll-out in low-income and middle-income countries
For those who can endure the adverse events, chimeric antigen receptor (CAR) T-cell therapy holds enormous promise. Axicabtagene ciloleucel was approved by t…
The Lancet
Read full story
Cancer CAR T therapy: What are the benefits and stakes?
The last decade has been termed the immunotherapy decade in the oncology-immunology sphere – thanks to the rapid and successful research and development pipe…
Express Pharma
Read full story
Kiran Mazumdar-Shaw on her career: ‘I call myself an accidental entrepreneur’
From a 25-year-old seeking finances for a small start-up to a billionaire businesswoman, Kiran Mazumdar-Shaw has come a long way. That small start-up in Indi…
Chemical & Engineering News
Read full story
India could be instrumental in lowering price of CAR T-cell therapy
India could play a key role in driving down the exorbitant cost of emerging cell and gene therapies, with a combination of comparatively cheap labor and effi…
BioWorld
Read full story
Our investment in Immuneel Therapeutics
Our India Ventures team today announced an investment in Immuneel Therapeutics, a venture focused on creating access to CAR-T and other cellular immunotherap…
Eightroads
Read full story
Biogen investment in Immuneel: Bringing CAR-T therapy to India
With nearly two million new cases and a million deaths each year in India, the war against cancer is amongst the most pressing crises in the country.
Global Regulatory & Consumer Insights
Read full story
Cut-price CAR-T cell therapies top India’s biotech agenda
Indian startups plan affordable CAR-T therapies—first for domestic use, then for the global market.
Nature Biotechnology
Read full story
From beer to bispecifics and beyond
India’s biotech scene is buzzing, with over 600 companies and 2,800 startups which collectively contributed approximately US$12 billion to the country’s econ…
Asian Scientist Magazine
Read full story
Immuneel’s radical approach to fight cancer
Biotech veteran Kiran Mazumdar-Shaw, oncologist Siddhartha Mukherjee, and Boston VC Kush Parmar team up to found Immuneel to bring cell therapy to cancer pat…
The Ken
Read full story
Cancer: Can Cell-Therapy reverse medicine’s battle? Dr. Siddhartha Mukherjee talks to Barkha Dutt
MOJO Story
See Video
Off The Cuff with Dr. Siddhartha Mukherjee
The Print
See Video
Kiran Mazumdar Shaw of Biocon and oncologist Siddhartha Mukherjee bring CAR T-cell therapy to cancer patients in India
Biocon chairperson Kiran Mazumdar Shaw, Indian-American oncologist and author Dr Siddhartha Mukherjee and Kush Parmar, managing partner at 5AM Ventures, are …
CNBC TV18
Read full story
Indian cancer patients may get access to CAR T-cell therapy in 8 months, says Dr Siddhartha Mukherjee
Indian-American oncologist and Pulitzer prize-winning author Dr Siddhartha Mukherjee has joined hands with Biocon Chairperson Kiran Mazumdar Shaw to bring in…
CNBC TV18
Read full story
Indian cancer patients may get access to car t-cell therapy in 8 months, says Dr. Siddhartha Mukherjee
CNBC TV18
See Video
Bringing CAR T to India
A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in Ind…
BioCentury
Read full story